Bavituximab: New Targeted Therapy Shows Promising Survival Benefit in Phase II NSCLC Trial
Article
While the main story coming out of the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology focused on the relatively disappointing results of the PointBreak trial, one positive trial received quite a bit of attention. Dr.